Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma

Doreen M. Agnese, Shahab F. Abdessalam, William E. Burak, Mark W. Arnold, Denise Soble, George H. Hinkle, Donn Young, M. B. Khazaeli, Edward W. Martin

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Background: CC49 is a monoclonal antibody directed against a pancarcinoma antigen (TAG-72) expressed by colorectal cancers. The use of murine CC49 in radioimmunoguided surgery (RIGS) was problematic because of the human anti-mouse antibodies (HAMA) generated. This study was designed to assess the clearance, safety, and effectiveness of localization of a complimentarity determining region (CDR)-grafted humanized domain-deleted antitumor CC49 antibody (HuCC49ΔCH2). Methods: After thyroid blockade, 1 mg of HuCC49ΔCH2 radiolabeled with 2 mCi of iodine-125 was administered. All patients subsequently underwent traditional exploration followed by a survey with the gamma-detecting probe. In five patients, exploration was performed 10 to 24 days after injection, when precordial counts were sufficiently low (<30 counts per 2 seconds [cp2s]). Traditionally suggestive and probe-positive tissue was biopsied or excised and examined for the presence of carcinoma, when considered appropriate by the operating surgeon. Serum was assessed for HAMA. Results: Seventeen sites were identified as suggestive of carcinoma on traditional exploration and 21 by RIGS. Of these, pathologic correlation was obtained in 15. The sensitivity of RIGS was 92%, and the positive predictive value was 100%. None of the patients expressed significant HAMA. Conclusions: This initial study indicates that the HuCC49ΔCH2 monoclonal antibody, when used with RIGS, is safe and sensitive in detecting recurrent intra-abdominal colon cancer.

Original languageEnglish (US)
Pages (from-to)197-202
Number of pages6
JournalAnnals of Surgical Oncology
Volume11
Issue number2
DOIs
StatePublished - Dec 1 2004

Keywords

  • Colorectal carcinoma
  • Monoclonal antibody
  • RIGS
  • Recurrent

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC <sub>H</sub>2) to localize recurrent colorectal carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Agnese, D. M., Abdessalam, S. F., Burak, W. E., Arnold, M. W., Soble, D., Hinkle, G. H., Young, D., Khazaeli, M. B., & Martin, E. W. (2004). Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma. Annals of Surgical Oncology, 11(2), 197-202. https://doi.org/10.1245/ASO.2004.05.010